SG11202012858QA - Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof - Google Patents
Crystal form of compound for inhibiting the activity of cdk4/6 and use thereofInfo
- Publication number
- SG11202012858QA SG11202012858QA SG11202012858QA SG11202012858QA SG11202012858QA SG 11202012858Q A SG11202012858Q A SG 11202012858QA SG 11202012858Q A SG11202012858Q A SG 11202012858QA SG 11202012858Q A SG11202012858Q A SG 11202012858QA SG 11202012858Q A SG11202012858Q A SG 11202012858QA
- Authority
- SG
- Singapore
- Prior art keywords
- cdk4
- inhibiting
- activity
- compound
- crystal form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018092194 | 2018-06-21 | ||
| PCT/CN2019/092239 WO2019242719A1 (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012858QA true SG11202012858QA (en) | 2021-02-25 |
Family
ID=68983152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012858QA SG11202012858QA (en) | 2018-06-21 | 2019-06-21 | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210261546A1 (ko) |
| EP (1) | EP3812386A4 (ko) |
| JP (1) | JP7430656B2 (ko) |
| KR (1) | KR20210024004A (ko) |
| CN (2) | CN113861191B (ko) |
| AU (1) | AU2019290722B2 (ko) |
| BR (1) | BR112020026052A2 (ko) |
| CA (1) | CA3104365A1 (ko) |
| EA (1) | EA202190036A1 (ko) |
| IL (1) | IL279579B2 (ko) |
| MX (1) | MX2020013847A (ko) |
| PH (1) | PH12020552236A1 (ko) |
| SG (1) | SG11202012858QA (ko) |
| TW (1) | TWI786303B (ko) |
| WO (1) | WO2019242719A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117222411A (zh) * | 2021-03-24 | 2023-12-12 | 贝达药业股份有限公司 | 药物组合、包含其的试剂盒及其用途 |
| WO2023131179A1 (zh) * | 2022-01-05 | 2023-07-13 | 贝达药业股份有限公司 | 苯并咪唑衍生物或其盐在治疗白血病中的用途 |
| CN115872923B (zh) * | 2022-12-29 | 2023-04-28 | 成都泰和伟业生物科技有限公司 | 一种化合物及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105294655B (zh) * | 2014-07-26 | 2019-03-15 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| CN104592251B (zh) * | 2015-01-23 | 2019-10-01 | 上海复星医药产业发展有限公司 | 4-(稠杂环取代氨基)-1h-吡唑-3-甲酰胺类化合物及其用途 |
| TWI696617B (zh) * | 2015-04-28 | 2020-06-21 | 大陸商上海復尚慧創醫藥研究有限公司 | 特定蛋白質激酶抑制劑 |
| CN107690431A (zh) * | 2015-07-08 | 2018-02-13 | 豪夫迈·罗氏有限公司 | 作为RORc调节剂的芳基磺内酰胺衍生物 |
| CN106608879A (zh) * | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| WO2017102796A1 (en) * | 2015-12-16 | 2017-06-22 | F. Hoffmann-La Roche Ag | HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS |
| TWI646094B (zh) * | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
| CA3047876C (en) * | 2016-12-22 | 2023-08-29 | Betta Pharmaceuticals Co., Ltd | Benzimidazole derivatives, preparation methods and uses thereof |
| CN111315379A (zh) * | 2017-08-15 | 2020-06-19 | 北京轩义医药科技有限公司 | Cdk4/6抑制剂及其用途 |
-
2019
- 2019-06-21 CN CN202111208432.8A patent/CN113861191B/zh active Active
- 2019-06-21 IL IL279579A patent/IL279579B2/en unknown
- 2019-06-21 AU AU2019290722A patent/AU2019290722B2/en active Active
- 2019-06-21 JP JP2020571503A patent/JP7430656B2/ja active Active
- 2019-06-21 KR KR1020217001384A patent/KR20210024004A/ko unknown
- 2019-06-21 EP EP19822566.6A patent/EP3812386A4/en active Pending
- 2019-06-21 US US17/254,097 patent/US20210261546A1/en active Pending
- 2019-06-21 WO PCT/CN2019/092239 patent/WO2019242719A1/zh unknown
- 2019-06-21 BR BR112020026052-5A patent/BR112020026052A2/pt unknown
- 2019-06-21 TW TW108121799A patent/TWI786303B/zh active
- 2019-06-21 CA CA3104365A patent/CA3104365A1/en active Pending
- 2019-06-21 SG SG11202012858QA patent/SG11202012858QA/en unknown
- 2019-06-21 CN CN201980037275.3A patent/CN112424202B/zh active Active
- 2019-06-21 MX MX2020013847A patent/MX2020013847A/es unknown
- 2019-06-21 EA EA202190036A patent/EA202190036A1/ru unknown
-
2020
- 2020-12-21 PH PH12020552236A patent/PH12020552236A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL279579B (en) | 2022-10-01 |
| CN113861191B (zh) | 2023-09-19 |
| US20210261546A1 (en) | 2021-08-26 |
| EA202190036A1 (ru) | 2021-03-24 |
| EP3812386A4 (en) | 2022-03-30 |
| WO2019242719A1 (zh) | 2019-12-26 |
| TW202016114A (zh) | 2020-05-01 |
| CN112424202A (zh) | 2021-02-26 |
| TWI786303B (zh) | 2022-12-11 |
| CA3104365A1 (en) | 2019-12-26 |
| JP7430656B2 (ja) | 2024-02-13 |
| AU2019290722A1 (en) | 2021-01-28 |
| IL279579B2 (en) | 2023-02-01 |
| CN112424202B (zh) | 2021-09-17 |
| AU2019290722B2 (en) | 2023-12-21 |
| JP2021529175A (ja) | 2021-10-28 |
| BR112020026052A2 (pt) | 2021-03-23 |
| EP3812386A1 (en) | 2021-04-28 |
| MX2020013847A (es) | 2021-04-28 |
| KR20210024004A (ko) | 2021-03-04 |
| PH12020552236A1 (en) | 2021-06-28 |
| IL279579A (en) | 2021-03-01 |
| CN113861191A (zh) | 2021-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304526A (en) | Production of compounds and preparations to inhibit the activity of shp2 | |
| IL280331A (en) | Tricyclic compounds to inhibit the activity of SHP2 | |
| PT3468972T (pt) | Compostos e composições para inibir a atividade da shp2 | |
| IL271149A (en) | Compounds for modulating s1p1 activity and methods of using them | |
| IL279579A (en) | A crystalline form of a compound for inhibiting the activity of CDK4/6 and its use | |
| SG11202011513RA (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| ZA202106304B (en) | Heterocyclic compound and use thereof | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| GB201820450D0 (en) | Compound and its use for the treatment of alpha1-antitryspin deficiency | |
| SG11202012289UA (en) | Kdm1a inhibitors for the treatment of disease | |
| EP3621615A4 (en) | APOPTOSIS 1 SIGNAL REGULATION KINASE INHIBITORS AND THEIR METHODS OF USE | |
| IL277600A (en) | AXLkinase inhibitors and their use | |
| EP3787621A4 (en) | APOPTOSIS SIGNAL REGULATING KINASE 1 INHIBITORS CONTAINING TETRAZOLES AND METHODS OF USE THEREOF | |
| IL286697A (en) | Neurogulin-4 compounds and methods of use | |
| IL276912A (en) | Heterocyclic compound and its use | |
| IL308476A (en) | Inhibitors of the menin-mil interaction | |
| GB201918404D0 (en) | Compounds and their use for the treatment of aplha1-antitrypsin deficiency | |
| EP3816156A4 (en) | RADIOACTIVE COMPOUND FOR THE TREATMENT OF MELANOMA AND USE THEREOF | |
| EP3594198A4 (en) | USE OF DMSO IN THE SYNTHESIS OF OLEACEIN AND OLEOCANTHAL | |
| ZA202100101B (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| IL290902A (en) | The compounds for the detection of beta-lactamases and the methods of their use | |
| ZA202101589B (en) | Crystal form of tri-cycle compound and application thereof | |
| EP4051270A4 (en) | 4-AMINO-IMODAZOCINOLINE COMPOUNDS AND USES THEREOF | |
| SG11202104374WA (en) | Heterocyclic compounds for the treatment of epilepsy | |
| EP3604310A4 (en) | CDC-7 INHIBITOR COMPOUNDS AND USE THEREOF IN THE TREATMENT OF NEUROLOGICAL DISEASES |